The drug pricing debate is top of mind with manufacturers, payers, governments, patients, and the medical professionals who treat them. In this issue of CRA Insights: Life Sciences we examine some of these issues.
The socioeconomic impact of rare diseases: An analysis of the evidence in middle-income countries
Worldwide, it is estimated that over 300 million people are living with one or more of the 6,000 to 8,000 identified rare conditions, yet the impact of rare...